3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Other hematologic neoplasm
1
Lymphoid
1
Dermatologic
1
CNS
1
Conditions
Melanoma
7
Carcinoma, Renal Cell
3
Triple Negative Breast Neoplasms
2
Recurrence
2
Neoplasm Metastasis
2
Colorectal Neoplasms
2
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Skin Neoplasms
1
Sarcoma, Ewing
1
Sarcoma
1
Rhabdomyosarcoma
1
Neuroblastoma
1
Neoplasms
1
Medulloblastoma
1
Lymphoma, Non-Hodgkin
1
Lymphoma
1
Leukemia, B-Cell
1
Leukemia
1
Glioma
1
Ependymoma
1
Carcinoma, Transitional Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Merkel Cell
1
Interventions
sonidegib
2
Etoposide
2
Carboplatin
2
tipifarnib
1
merphos
1
entinostat
1
carboxyamido-triazole
1
bempegaldesleukin
1
Vincristine
1
Thrombopoietin
1
Thalidomide
1
Paclitaxel
1
Oxaliplatin
1
Nivolumab
1
NVP-LEQ506
1
Methotrexate
1
Mental Status and Dementia Tests
1
LY2940680
1
Irinotecan
1
Immunologic Techniques
1
Ifosfamide
1
Granulocyte Colony-Stimulating Factor
1
Filgrastim
1
Fentanyl
1
Docetaxel
1
Cyclophosphamide
1
90Y-octreotide, DOTA-Tyr(3)-
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Medulloblastoma
×
bempegaldesleukin
×
Dermatologic
×
Clear all
NCT04730349
2023-03-24
PIVOT IO 020
Bristol-Myers Squibb
Phase 1/2
Terminated
15 enrolled
14 charts